컴퓨터 보조 신약 개발(CAAD) 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global computer-aided drug discovery market size is expected to reach USD 14.62 Billion in 2034 from USD 5.20 Billion in 2025, growing at a CAGR of 12.17% during 2026-2034.This market is expanding as pharmaceutical and biotechnology companies increasingly use computational technologies to accelerate drug research and improve the efficiency of early-stage development. Computer-aided drug discovery uses methods such as molecular modeling, virtual screening, molecular docking, and computational chemistry to identify and evaluate potential drug candidates. These approaches can help researchers investigate interactions between compounds and biological targets before advancing selected candidates to laboratory testing. Growing demand for more efficient drug development, combined with advances in computing power and biological data availability, is encouraging the adoption of computational tools across pharmaceutical research.

Market growth is driven by increasing pharmaceutical research expenditure, advances in artificial intelligence, and the growing availability of genomic, proteomic, and structural biology data. Machine learning models can help identify promising compounds, predict molecular properties, and prioritize candidates for experimental validation. Cloud computing and specialized software platforms are making computational resources more accessible to research organizations. Pharmaceutical companies are also collaborating with technology providers and biotechnology firms to combine computational predictions with laboratory experiments. These developments are helping researchers investigate complex biological targets, improve screening efficiency, and explore potential treatments for diseases with limited therapeutic options.

The future prospects of this market will depend on improvements in predictive accuracy, data quality, computational models, and integration with experimental research. Artificial intelligence may increasingly support target identification, molecular design, toxicity prediction, and optimization of candidate compounds. Generative models could help researchers explore new molecular structures with desired characteristics, while improved simulation methods may provide deeper insights into biological interactions. However, limitations involving incomplete datasets, model reliability, experimental validation, and regulatory expectations will remain important considerations. Combining computational approaches with laboratory evidence and clinical research will be essential for translating promising discoveries into safe and effective medicines.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Structure Based Drug Design
• Ligand-Based Drug Design
• Sequence-Based Approaches

By Therapeutic Area

• Oncology
• Neurology
• Cardiovascular Disease
• Respiratory Disease
• Diabetes
• Others

By End User

• Pharmaceutical Companies
• Biotechnology Companies
• Research Laboratories

COMPANIES PROFILED

• Schrodinger, Exscientia, Insilico Medicine, BenevolentAI, Recursion Pharmaceuticals, Atomwise, XtalPi, Relay Therapeutics, Genesis Therapeutics, Nimbus Therapeutics, Deep Genomics, Verge Genomics, Owkin, Valence Discovery, Generate Biomedicines, Iktos, Evotec, Cyclica, Numerate, Absci

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Structure Based Drug Design Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Ligand-Based Drug Design Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Sequence-Based Approaches Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapeutic Area
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Respiratory Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Research Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Therapeutic Area
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Therapeutic Area
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Therapeutic Area
  • 7.4.3 By End User
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Therapeutic Area
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Therapeutic Area
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL COMPUTER-AIDED DRUG DISCOVERY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Schrodinger
  • 9.2.2 Exscientia
  • 9.2.3 Insilico Medicine
  • 9.2.4 BenevolentAI
  • 9.2.5 Recursion Pharmaceuticals
  • 9.2.6 Atomwise
  • 9.2.7 XtalPi
  • 9.2.8 Relay Therapeutics
  • 9.2.9 Genesis Therapeutics
  • 9.2.10 Nimbus Therapeutics
  • 9.2.11 Deep Genomics
  • 9.2.12 Verge Genomics
  • 9.2.13 Owkin
  • 9.2.14 Valence Discovery
  • 9.2.15 Generate Biomedicines
  • 9.2.16 Iktos
  • 9.2.17 Evotec
  • 9.2.18 Cyclica
  • 9.2.19 Numerate
  • 9.2.20 Absci